9 Recruiting Colorectal Cancer Clinical Trials in Texas
Explore active colorectal cancer research studies enrolling across Texas. Verify eligibility and contact site coordinators.
📍 Find Near Me by DistanceRecruiting Colorectal Cancer Studies in Texas
🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research
Precision-MRD: Prospective Observational Study of Biomarker-directed Systemic Therapy for Colorectal Cancer Patients With Minimal Residual Disease
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
📍 University of Texas Southwestern Medical Center — Dallas, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment
📍 The University of Texas MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic
Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer
📍 University of Texas Southwestern Medical Center — Dallas, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase2 💊 Investigational Drug / Biologic
TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
📍 MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔ 🟢 Recruiting Interventional Protocol 📊 Observational Clinical Research
Early-Onset Colorectal Cancer Patients Too Young for Screening
📍 Methodist Dallas Medical Center- Clinical Research Institute — Dallas, Texas
View Study & Checklist ➔